Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera - A Randomized Open Label Global Multicenter Study (PARADIGM-PV)

NCT06290765 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT06290765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06290765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera - A Randomized Open Label Global Multicenter Study (PARADIGM-PV)
Lead sponsor
PharmaEssentia
Phase
Phase 4
Overall status
Withdrawn
Start date
August 1, 2026
Completion date
June 30, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasm, polycythemia vera